OncoLink Cancer Treatment and Resources
OncoLink Cancer Treatment and Resources
Link to OncoLink

Prevent Hair Loss with Tempol

Ultima Vez Modificado: 1 de octubre del 2006

Question

Dear OncoLink "Ask The Experts,"

I saw the article on Tempol and alopecia and was wondered about the follow-up data on that study. I already had whole brain radiation at a high dose (3750cGy). I am wondering if researchers have found anything to help with regrowth in this type of case.

Answer

James M. Metz, MD, Editor-in-Chief of OncoLink and Assistant Professor of Radiation Oncology at the Hospital of the University of Pennsylvania, responds:

Tempol is a type of antioxidant (a substance that blocks DNA-damaging oxidation, thus preventing free radical formation and normal tissue injury). Radiation therapy is believed to fight cancer by oxidizing and destroying tumor DNA. Thus, Tempol is being actively investigated for its promising role as a radioprotector (substance that protects cells of the surrounding normal tissue from radiation damage). It has already been found to have many possible applications in cancer patients, and thus far appears to be very safe and well tolerated in humans.

We completed a phase II trial utilizing topical Tempol as a way to decrease or prevent hair loss caused by radiation to the head, and have documented good results. We will next be doing an expanded phase II study prior to moving towards a larger, multi-center, randomized Phase III trial. Tempol is also being studied as a topical agent for skin protection, as well as in the intravenous form to protect the salivary glands during mouth radiation for head and neck cancer. In terms of non-oncologic disciplines, Tempol is being evaluated for pre-eclampsia during pregnancy, hypertension, kidney protection and shock.

Ultimately, at this time, it is used to prevent hair loss caused by radiation to the head. As of yet, there is no product proven to help hair regrow faster under these conditions. There are numerous products that are marketed and claim to do this, but none have been studied in clinical settings with rigorous scientific standards.

OncoLink I wish u knew...

Dr. Vapiwala discusses the Affordable Care Act and access to healthcare. Read more.

Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet

Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy

Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies

Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer

Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults

OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews


Ask the Experts
Brown Bag Chat
Tracy's Corner

About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement

OncoLink Cancer Resources RSS What's New RSS